查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552551

骨质疏鬆症治疗药物市场规模、份额和趋势分析报告：按药物类别、类型、分销管道、地区和细分市场预测，2024-2030年

Osteoporosis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Branded, Generics), By Type (Bisphosphates, Parathyroid Hormone Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格
简介目录

骨质疏鬆症治疗市场的成长与趋势

Grand View Research, Inc.最新报告显示，到2030年，全球骨质疏鬆症治疗市场规模预计将达到188亿美元，2024年至2030年复合年增长率为3.5%。

据估计，不健康生活方式的激增将导致骨质疏鬆症恶化和盛行率增加，从而推动预测期内骨质疏鬆症治疗市场的发展。

此外，专利到期数量的增加增加了使用现有药物药物学名药的临床紧迫性，预计这将在预测期内推动非专利骨质疏鬆症治疗市场的发展。上述因素的结合显示未来几年存在巨大的潜在成长机会。

此外，加强提高患者和医生对骨质疏鬆症治疗的意识层级也有望扩大预测期内骨质疏鬆症市场的成长潜力。例如，国家骨质疏鬆症基金会 (NOF) 是一家负责国家骨骼健康联盟和骨折联络服务 (FLS) 护理协调计划的医疗保健组织，该组织致力于提高意识层级并向医疗保健专业人员提供培训。

骨质疏鬆症治疗市场报告亮点

  • 到2023年，品牌药将在产品领域占据压倒性份额。这一主导份额是由于双磷酸盐、活化因数配体抑制剂的广泛使用，它们在治疗骨质疏鬆症方面具有高效能。
  • 由于未来几年专利持续到期以及新兴市场对负担得起的药物的高度临床紧迫性，预计学名药将继续保持良好的复合年增长率。
  • 2023年，由于现有公司广泛参与品牌治疗的商业化，北美在全球骨质疏鬆症治疗市场中占据最大份额。
  • 由于政府采取积极倡议宣传骨质疏鬆症治疗相关讯息，预计亚太地区将以指数复合年增长率成长。
  • 主要参与企业正在采取永续性策略，以加速骨质疏鬆症治疗的采用，以获得竞争优势。例如，阿特维斯公司宣布收购 Warner Chilcott PLC 以扩大产品系列。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章全球骨质疏鬆症治疗市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 全球骨质疏鬆症治疗市场分析工具
    • 波特的分析
    • PESTEL分析

第四章全球骨质疏鬆症治疗市场：药物类别、估计与趋势分析

  • 细分仪表板
  • 全球骨质疏鬆症治疗市场：2023 年和 2030 年药物类别变化分析
  • 品牌
  • 非专利的

第五章全球骨质疏鬆症治疗市场：类型、估计与趋势分析

  • 细分仪表板
  • 全球骨质疏鬆症治疗市场：类型变异分析，2023 年和 2030 年
  • 双磷酸盐
  • 副甲状腺素治疗
  • 抑钙素
  • 选择性雌激素抑制剂调变器
  • 活化因数配体抑制剂
  • 其他的

第六章全球骨质疏鬆治疗市场：通路、估计与趋势分析

  • 细分仪表板
  • 全球骨质疏鬆症治疗市场：2023年及2030年通路波动分析
  • 医院药房
  • 零售药房
  • 在线的

第七章全球骨质疏鬆症治疗市场：区域估计与趋势分析

  • 2023年及2030年全球骨质疏鬆症治疗市场占有率（按地区），百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Amgen Inc.
    • Eli Lilly and Company
    • Merck &Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • GlaxoSmithKline plc.
    • Radius Health, Inc.
    • UCB SA
    • Teva Pharmaceutical Industries Ltd.
    • Roche Holding AG
简介目录
Product Code: GVR-1-68038-762-9

Osteoporosis Drugs Market Growth & Trends:

The global osteoporosis drugs market size is expected to reach USD 18.80 billion by 2030 and is projected to grow at a CAGR of 3.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Osteoporosis Drugs Market Report Highlights:

  • Branded drugs held the dominant share of the product segment in 2023. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy
  • Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies
  • In 2023, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics
  • Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care
  • The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Osteoporosis Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Global Osteoporosis Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Global Osteoporosis Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Osteoporosis Drugs Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Branded
    • 4.3.1. Branded Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Generics
    • 4.4.1. Generics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Osteoporosis Drugs Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Osteoporosis Drugs Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Bisphosphonates
    • 5.3.1. Bisphosphonates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Parathyroid Hormone Therapy
    • 5.4.1. Parathyroid Hormone Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Calcitonin
    • 5.5.1. Calcitonin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Selective Estrogen Inhibitors Modulator
    • 5.6.1. Selective Estrogen Inhibitors Modulator Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Rank Ligand Inhibitor
    • 5.7.1. Rank Ligand Inhibitor Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Osteoporosis Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Osteoporosis Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online
    • 6.5.1. Online Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Global Osteoporosis Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Global Osteoporosis Drugs Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Osteoporosis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Amgen Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Eli Lilly and Company
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Merck & Co., Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Novartis AG
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Pfizer Inc.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. GlaxoSmithKline plc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Radius Health, Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. UCB S.A.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Teva Pharmaceutical Industries Ltd.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Roche Holding AG
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives